Sam Brusco, Associate Editor06.02.21
STERIS plc completed the previously announced acquisition of Cantel Medical, global provider of infection prevention products and services to endoscopy, dental, dialysis, and life sciences customers.
“We are pleased to announce the closing of the Cantel Medical acquisition, which will complement and extend STERIS’s product and service offerings, global reach and customers,” Walt Rosebrough, president and CEO of STERIS told the press. “We welcome Cantel people to the STERIS team, and look forward to working together to create more value for our Customers, our people, and our shareholders.”
Guggenheim Securities served as financial advisor to STERIS and Jones Day as legal counsel. JPMorgan Chase Bank, N.A., served as sole lead arranger and bookrunner in respect of certain financing. Centerview Partners LLC served as exclusive financial advisor to Cantel and Wachtell, Lipton, Rosen & Katz as legal counsel.
“We are pleased to announce the closing of the Cantel Medical acquisition, which will complement and extend STERIS’s product and service offerings, global reach and customers,” Walt Rosebrough, president and CEO of STERIS told the press. “We welcome Cantel people to the STERIS team, and look forward to working together to create more value for our Customers, our people, and our shareholders.”
Guggenheim Securities served as financial advisor to STERIS and Jones Day as legal counsel. JPMorgan Chase Bank, N.A., served as sole lead arranger and bookrunner in respect of certain financing. Centerview Partners LLC served as exclusive financial advisor to Cantel and Wachtell, Lipton, Rosen & Katz as legal counsel.